Omezolan 40 (Omeprazole)

Omeprazole, the active ingredient in Omezolan 40, is a Proton Pump Inhibitor presented as a 40 mg tablet for oral use. It reduces gastric acid secretion and is used to treat acid‑related disorders in adults and children. GNH USA supplies Omezolan 40 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Omezolan 40 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related conditions: - Gastro‑esophageal reflux disease (GERD): provides symptomatic relief and promotes healing of erosive esophagitis. - Peptic ulcer disease: supports ulcer healing and reduces recurrence risk. - Zollinger‑Ellison syndrome: controls gastric acid hypersecretion associated with the condition. - Helicobacter pylori eradication regimens: used as part of combination therapy to improve eradication rates. - Erosive gastritis: aids mucosal healing by maintaining a higher gastric pH.

Omeprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: usually self‑limiting. - Nausea or vomiting: transient gastrointestinal upset. - Abdominal pain or discomfort: mild cramping. - Flatulence: excess gas production. - Constipation: occasional bowel habit change.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rash, swelling, airway compromise. - Clostridioides difficile‑associated colitis: watery diarrhea, abdominal pain. - Acute interstitial nephritis: renal impairment, hematuria. - Osteoporotic fractures: increased risk with long‑term use. - Hypomagnesemia: low serum magnesium, muscle cramps, arrhythmia. - Vitamin B12 deficiency: anemia, neuropathy with prolonged therapy.

When prescribing Omeprazole, consider the following precautions: - Assess renal and hepatic function: dose adjustment may be required in severe impairment. - Review long‑term use: evaluate need after 8‑12 weeks to avoid potential complications. - Monitor for infection risk: prolonged acid suppression may increase susceptibility to gastrointestinal infections. - Counsel on drug interactions: many agents alter omeprazole metabolism or efficacy. - Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Omeprazole can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk. - Atazanavir or other protease inhibitors: decreased absorption, loss of antiviral efficacy.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR, monitor coagulation parameters. - Phenytoin: reduced serum levels, monitor seizure control. - Methotrexate (high dose): increased exposure, watch for toxicity. - Digoxin: modest rise in serum concentration, assess for signs of toxicity.